Samsung Bioepis reveals clinical trial results of SB3 at ASCO in U.S.

Published: 2018-06-04 18:49:45

Updated: 2018-06-04 18:49:45

Samsung Bioepis(CEO/President Han-Seung Ko) revealed the 1-year clinical trial result of SB3(Herceptin biosimilar, generic name: trastuzumab, European name: Ontruzant, Korean name: Samfenet), a breast cancer therapy.

The recently announced clinical trial result is the first 1-year tracking result of the total 5-year clinical trial, revealed at the website of ‘2018 American Society of Clinical ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.